Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion ...
Citigroup analyst Patrick Donnelly downgrades QuidelOrtho (NASDAQ:QDEL) from Buy to Neutral and lowers the price target from...
Key Features and Benefits:Triple Detection Capability: Differentiates influenza A/B and COVID-19 in one test.Fast Results: Clea...
UBS analyst Lu Li maintains QuidelOrtho (NASDAQ:QDEL) with a Neutral and lowers the price target from $29 to $26.
Citigroup analyst Patrick Donnelly maintains QuidelOrtho (NASDAQ:QDEL) with a Buy and lowers the price target from $50 to $40.
QuidelOrtho (NASDAQ:QDEL) affirms FY2025 Adj EPS guidance from $2.07-$2.57 to $2.07-$2.57 vs $2.40 analyst estimate. Affirms FY...
QuidelOrtho (NASDAQ:QDEL) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.01 by ...
